Effect of the GSK2245035 on the Allergen-induced Asthmatic Response
Status:
Completed
Trial end date:
2018-05-04
Target enrollment:
Participant gender:
Summary
This study will assess whether Toll like receptor 7 (TLR7)-mediated pharmacology, with
intranasal (i.n.) GSK2245035 20 nanogram (ng) administered weekly for a period of 8 weeks,
will lead to reduced allergic reactivity in the lower airways in subjects with mild allergic
asthma.
This will be a randomised, double-blind (sponsor open), placebo-controlled, parallel group,
8-week treatment study.
The study will consist of a screening period of up to approximately 4 weeks (involving two
screening visits), a blinded treatment period of 8 weeks, followed by a follow-up period of
up to 3 months. The total duration of the study for each subject will therefore be a maximum
of approximately 6 months.